

DECEMBER 23, 2021

LTC COVID-19 UPDATE

Presented by:

Lori Davenport,

Director of Regulatory & Clinical Affairs



Agenda

- Pfizer's Paxlovid gets EUA
- Visitation Reminders
- COVID-Ready and EMResources
- December 30th weekly update is cancelled
- Weekly webinar will resume January 6th 2022



EUA Issued – Pfizer's Paxlovid

- Treatment of mild-to-moderate coronavirus disease in adults and pediatric patients (12 and older weighing at least 40 kilograms or 88 pounds) with positive results of direct SARS-CoV-2 testing and at high risk for progression to severe COVID-19, including hospitalization or death.
- Prescription only
- Initiated as soon as possible within five days of symptom onset
- Pill form



EUA Issued – Pfizer's Paxlovid

- Not for pre-exposure or post exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19.
- Not a substitute for vaccination



EUA Issued – Pfizer's Paxlovid

- Inhibits a SARS-CoV-2 protein to stop the virus from replicating.
- Three tablets taken together orally twice a day for five days for a total of 30 tablets.



EUA Issued – Pfizer's Paxlovid

- EUA is different than an FDA approval
- Potential benefits outweigh the potential risks
- Data supporting the EUA are from EPIC-HR, a randomized double-blind, placebo-controlled clinical trail.



Possible Side Effects of Paxlovid

- Impaired sense of taste
- Diarrhea
- High blood pressure
- Muscle aches
- Possible drug interactions with other drugs taken
- Caution in HIV that is uncontrolled or undiagnosed
- Liver damage
- Some drugs are contraindicated

For a complete list of drugs that should not be taken in combination with Paxlovid, see the [fact sheet](#) for healthcare providers.



Paxlovid

- Not recommended in patients with the following:
 - Severe kidney or severe liver impairment

A reduced dose may be considered in patients with moderate renal impairment – may or may not be right for these individuals.



Paxlovid

- Recommended Actions:
 - Provide fact sheets (attachment) to healthcare providers, residents and caregivers.



**Update your COVID-19 Ready Status in
EMResources**

Visitation Reminders



QUESTIONS?



THANK YOU!